The four-day event, held at the Boston Convention and Exhibition Center, marks the 32nd edition of the world’s largest biotechnology trade show.
“BIO 2025 offers Korean biotech companies an unparalleled global platform to showcase their technologies and establish transformative partnerships,” said Jurie Hwang, director of public and international relations at the Korea Biotechnology Industry Organization (KoreaBio).
The convention takes place against the backdrop of evolving pharmaceutical markets.
With the U.S. under renewed political pressure to curb rising drug prices, South Korean firms are eyeing the American biosimilar market, where several high-profile patents are nearing expiration.
South Korea’s pharmaceutical sector made a notable showing at this year’s gathering.
Samsung Biologics, Celltrion, Lotte Biologics and SK Biopharmaceuticals were among the major companies hosting large-scale booths aimed at securing global partnerships and licensing agreements.
reporter
Kim Dong-young
davekim0807@ajupress.com
Copyright ⓒ Aju Press All rights reserved.
View more comments